Atlanta, Georgia
Cancer biologic therapy trials in Atlanta, GA
58 cancer biologic therapy studies are recruiting participants at sites in Atlanta as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Atlanta at a glance
- 58 studies are recruiting at a site in Atlanta.
- By phase: Early Phase 1 (1), Phase 1 (10), Phase 1/2 (2), Phase 2 (20), Phase 2/3 (2), Phase 3 (22), Observational (1).
- By sponsor: university, hospital or other (24), industry (21), government (13).
- By research area: Lymphoma (23), Lung Cancer (17), Breast Cancer (9), Melanoma (5), Prostate Cancer (3), Pancreatic Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Atlanta
Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT06058377 · updated
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Nammi Therapeutics Inc
- Study site
- Emory University - Winship Cancer Institute
- Registry record
- NCT06582017 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.
Lung cancer studies recruiting in Atlanta
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT06287775 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northside Hospital
- Registry record
- NCT04267848 · updated
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Piedmont Atlanta Hospital ( Site 0121)
- Registry record
- NCT07554339 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Emory University School of Medicine-Phase I ( Site 0056) · Northside Hospital ( Site 0055) · Piedmont Atlanta Hospital ( Site 4000)
- Registry record
- NCT06312137 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT04181060 · updated
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Study site
- Emory University Winship Cancer Institute
- Registry record
- NCT06667908 · updated
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Phase 3
- All ages
- All sexes
- Sponsor
- Pierre Fabre Medicament
- Study site
- Arthur M Blank Hospital - Children's Healthcare of Atlanta
- Registry record
- NCT03394365 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT06116682 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT06616584 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Atlanta
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT03866382 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.
Melanoma studies recruiting in Atlanta
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Outpace Bio, Inc.
- Study site
- Emory - Winship Cancer Institute
- Registry record
- NCT07664735 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- Winship Cancer Institute, Emory University
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Atlanta, GA on ClinicalTrials.gov.
Lymphoma studies recruiting in Atlanta
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT03739814 · updated
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT06337318 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Arthur M Blank Hospital
- Registry record
- NCT06173518 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Healthcare of Atlanta - Arthur M Blank Hospital · Emory Proton Therapy Center · Emory Saint Joseph's Hospital
- Registry record
- NCT05675410 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT07003295 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Northside Hospital
- Registry record
- NCT07188558 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT03150693 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT05976763 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
- Registry record
- NCT06124157 · updated
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- Northside Hospital
- Registry record
- NCT06059391 · updated
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Phase 1
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- Northside Hospital
- Registry record
- NCT07020533 · updated
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
- Registry record
- NCT05633615 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Atlanta, GA on ClinicalTrials.gov.
Ask about studies near Atlanta
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections